Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 14/20 | 0.48 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383854 | 1.00 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL1239007 | 1.00 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL575976 | 1.00 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL29800472 | 1.00 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL2329989 | 1.00 | FAAH (0.54) | FAAHCA2CA1CA9CA12 | |
| Butane SCHEMBL2384362 | 0.97 | FAAH (0.52) | FAAHCA2CA1CA9CA12 | |
| Butane SCHEMBL2384367 | 0.97 | FAAH (0.52) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL27460969 | 0.97 | FAAH (0.52) | FAAHCA2CA1CA9CA12 | |
| SCHEMBL1341402 | 0.97 | FAAH (0.50) | FAAHCA2CA1CA9CA12 | |
| Butane SCHEMBL2384418 | 0.95 | FAAH (0.48) | FAAHCA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130164216-A1 | BLADDER CANCER TUMOR MARKER, ANTIBODY AND USE THEREOF | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2013-06-27 | — | — | US | claimed |
| US-9073995-B2 | Bladder cancer tumor marker, antibody and use thereof | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2015-07-07 | — | — | US | disclosed |
| US-20130164216-A1 | BLADDER CANCER TUMOR MARKER, ANTIBODY AND USE THEREOF | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20080227689-A1 | Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164216-A1 | BLADDER CANCER TUMOR MARKER, ANTIBODY AND USE THEREOF | B4GALT1, GALNT3, CSGALNACT1 | FAAH 3365/4885CA2 587/4885CA1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.